Oligodendroglioma-Pipeline Review, H1 2015

Oligodendroglioma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6462IDB
  • |
  • Pages: 94
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Oligodendroglioma-Pipeline Review, H1 2015


Global Markets Direct's, 'Oligodendroglioma-Pipeline Review, H1 2015', provides an overview of the Oligodendroglioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Oligodendroglioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Oligodendroglioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Oligodendroglioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Oligodendroglioma Overview 8

Therapeutics Development 9

Pipeline Products for Oligodendroglioma-Overview 9

Pipeline Products for Oligodendroglioma-Comparative Analysis 10

Oligodendroglioma-Therapeutics under Development by Companies 11

Oligodendroglioma-Therapeutics under Investigation by Universities/Institutes 12

Oligodendroglioma-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Oligodendroglioma-Products under Development by Companies 15

Oligodendroglioma-Products under Investigation by Universities/Institutes 16

Oligodendroglioma-Companies Involved in Therapeutics Development 17

Cavion LLC 17

Celgene Corporation 18

Celldex Therapeutics, Inc. 19

e-Therapeutics plc 20

Eli Lilly and Company 21

F. Hoffmann-La Roche Ltd. 22

Millennium Pharmaceuticals, Inc. 23

Novartis AG 24

Orbus Therapeutics, Inc. 25

Sanofi 26

Tocagen Inc. 27

Oligodendroglioma-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Combination Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

alisertib-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

bevacizumab-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CC-122-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Dendritic Cell Therapy for Gliomas-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Dendritic Cell Therapy for Oncology-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

DNX-2401-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

eflornithine hydrochloride-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ETS-2101-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

galunisertib-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

mibefradil dihydrochloride-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

panobinostat-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

plerixafor-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

rindopepimut-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Stem Cell Therapy for Glioma-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

vocimagene amiretrorepvec + flucytosine ER-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Oligodendroglioma-Recent Pipeline Updates 74

Oligodendroglioma-Dormant Projects 92

Appendix 93

Methodology 93

Coverage 93

Secondary Research 93

Primary Research 93

Expert Panel Validation 93

Contact Us 93

Disclaimer 94

List of Tables

Number of Products under Development for Oligodendroglioma, H1 2015 9

Number of Products under Development for Oligodendroglioma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Oligodendroglioma-Pipeline by Cavion LLC, H1 2015 17

Oligodendroglioma-Pipeline by Celgene Corporation, H1 2015 18

Oligodendroglioma-Pipeline by Celldex Therapeutics, Inc., H1 2015 19

Oligodendroglioma-Pipeline by e-Therapeutics plc, H1 2015 20

Oligodendroglioma-Pipeline by Eli Lilly and Company, H1 2015 21

Oligodendroglioma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 22

Oligodendroglioma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 23

Oligodendroglioma-Pipeline by Novartis AG, H1 2015 24

Oligodendroglioma-Pipeline by Orbus Therapeutics, Inc., H1 2015 25

Oligodendroglioma-Pipeline by Sanofi, H1 2015 26

Oligodendroglioma-Pipeline by Tocagen Inc., H1 2015 27

Assessment by Monotherapy Products, H1 2015 28

Assessment by Combination Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Oligodendroglioma Therapeutics-Recent Pipeline Updates, H1 2015 74

Oligodendroglioma-Dormant Projects, H1 2015 92

List of Figures

Number of Products under Development for Oligodendroglioma, H1 2015 9

Number of Products under Development for Oligodendroglioma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Cavion LLC

Celgene Corporation

Celldex Therapeutics, Inc.

e-Therapeutics plc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Millennium Pharmaceuticals, Inc.

Novartis AG

Orbus Therapeutics, Inc.


Tocagen Inc.

Oligodendroglioma Therapeutic Products under Development, Key Players in Oligodendroglioma Therapeutics, Oligodendroglioma Pipeline Overview, Oligodendroglioma Pipeline, Oligodendroglioma Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com